1.460SEK+4.29%Mkt Cap: 160.88M SEKP/E: —Last update: 2026-05-13
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the devel…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-11.67
PEG—
P/B4.90
P/S—
EV/EBITDA-2.42
EV/Revenue—
EPS (TTM)-0.55
EPS (Forward)-0.12
Cash Flow & Leverage
FCF Yield-10.62%
FCF Margin—
Operating CF-34.59M SEK
CapEx (TTM)—
Net Debt/EBITDA1.02
Net Debt-47.78M SEK
Technical
SMA 501.571 (-7.1%)
SMA 2002.226 (-34.4%)
Beta-0.04
S&P 52W Chg24.23%
Avg Vol (30d)120.28K
Avg Vol (10d)157.56K
Technical Indicators
RSI (14)48.9
MACD-0.0419
MACD Signal-0.0599
MACD Hist.+0.0180
BB Upper1.513 SEK
BB Middle1.415 SEK
BB Lower1.318 SEK
BB Width13.73%
ATR (14)0.1183 SEK
Vol Ratio (20d)0.95x
52W Range
1.3004% of range4.950
52W High4.950 SEK
52W Low1.300 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-144.75%
ROA-80.71%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.08
Current Ratio2.33
Quick Ratio2.28
Book Value/Sh0.2860 SEK
Cash/Share0.4380 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.114.91M
Float69.17M
Insiders42.95%
Institutions9.07%
Analyst Consensus
Rating—
Target (Mean)5.000 SEK
Target Range5.000 SEK – 5.000 SEK
# Analysts1
Company
Market Cap160.88M SEK
Enterprise Value113.10M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-47.65M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees10
Last Price1.460 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—